ABILIFY ASIMTUFII Drug Patent Profile

« Back to Dashboard

Which patents cover Abilify Asimtufii, and what generic alternatives are available?

Abilify Asimtufii is a drug marketed by Otsuka and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in ABILIFY ASIMTUFII is aripiprazole. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify Asimtufii

A generic version of ABILIFY ASIMTUFII was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY ASIMTUFII

US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	6,225
Drug Prices:	Drug price information for ABILIFY ASIMTUFII
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY ASIMTUFII
What excipients (inactive ingredients) are in ABILIFY ASIMTUFII?	ABILIFY ASIMTUFII excipients list
DailyMed Link:	ABILIFY ASIMTUFII at DailyMed

See drug prices for ABILIFY ASIMTUFII

Pharmacology for ABILIFY ASIMTUFII

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ABILIFY ASIMTUFII

ABILIFY ASIMTUFII is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023		RX	Yes	Yes			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023		RX	Yes	Yes			Y

Expired US Patents for ABILIFY ASIMTUFII

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023

EU/EMA Drug Approvals for ABILIFY ASIMTUFII

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)	aripiprazole	EMEA/H/C/003803Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-30
Otsuka Pharmaceutical Netherlands B.V.	Abilify	aripiprazole	EMEA/H/C/000471Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	no	no	no	2004-06-04
Otsuka Pharmaceutical Netherlands B.V.	Abilify Maintena	aripiprazole	EMEA/H/C/002755Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.	Authorised	no	no	no	2013-11-14
Accord Healthcare S.L.U.	Aripiprazole Accord	aripiprazole	EMEA/H/C/004021Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-11-15
Zentiva, k.s.	Aripiprazole Zentiva	aripiprazole	EMEA/H/C/003899Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-25
Sandoz GmbH	Aripiprazole Sandoz	aripiprazole	EMEA/H/C/004008Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-08-20

International Patents for ABILIFY ASIMTUFII

See the table below for patents covering ABILIFY ASIMTUFII around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	090776
Argentina	126033
Australia	2013253374
Australia	2017228608
Australia	2019200060
Australia	2020204200

Supplementary Protection Certificates for ABILIFY ASIMTUFII

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119

Abilify Asimtufii Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: October 5, 2026

Abilify Asimtufii is Otsuka Pharmaceutical and Lundbeck’s twice-monthly long-acting injectable formulation of aripiprazole. The product received U.S. FDA approval in February 2023 for schizophrenia and maintenance monotherapy of bipolar I disorder in adults. Its commercial value comes from extending aripiprazole depot treatment from monthly to every two months, improving administration convenience and supporting retention in a long-acting injectable market that is expanding faster than many oral antipsychotic segments.

Standalone revenue for Abilify Asimtufii is not publicly disclosed. Otsuka and Lundbeck generally report aripiprazole long-acting injectable sales through broader product or franchise categories, principally Abilify Maintena and related aripiprazole products. The near-term financial trajectory therefore depends on conversion from Abilify Maintena, incremental penetration of long-acting injectable therapy, pricing, payer coverage, and the timing of generic and follow-on competition.

What is Abilify Asimtufii and how does it work?

Abilify Asimtufii is an extended-release injectable suspension containing aripiprazole, a dopamine D2 and D3 partial agonist and serotonin 5-HT1A partial agonist with serotonin 5-HT2A antagonist activity. It is administered once every two months after patients have been stabilized on an appropriate aripiprazole regimen.

Product	Active ingredient	Administration	Main U.S. indications	Sponsor
Abilify Asimtufii	Aripiprazole	720 mg or 960 mg every two months	Schizophrenia; bipolar I maintenance monotherapy	Otsuka Pharmaceutical and Lundbeck
Abilify Maintena	Aripiprazole	Monthly injection	Schizophrenia; bipolar I maintenance monotherapy	Otsuka Pharmaceutical and Lundbeck
Aristada	Aripiprazole lauroxil	Monthly to every six months, depending on dose and regimen	Schizophrenia	Alkermes
Invega Hafyera	Paliperidone palmitate	Every six months	Schizophrenia	Johnson & Johnson
Perseris	Risperidone	Monthly injection	Schizophrenia	Teva
Uzedy	Risperidone	Monthly or every two months	Schizophrenia	Teva

The product’s principal clinical and commercial distinction is dosing frequency. Patients can receive two months of treatment in one administration, reducing injection visits compared with Abilify Maintena. The label requires appropriate oral aripiprazole exposure before initiation and oral supplementation in specified circumstances to maintain therapeutic concentrations during the transition period. The FDA-approved label identifies 960 mg as the recommended dose, with 720 mg available when tolerability or other clinical considerations support dose reduction (FDA, 2023).

When did Abilify Asimtufii receive FDA approval?

The FDA approved Abilify Asimtufii on February 28, 2023, under NDA 217006. The approval expanded the aripiprazole long-acting injectable franchise rather than creating a new active pharmaceutical ingredient or a new therapeutic class.

The regulatory pathway was commercially efficient because:

1. Aripiprazole had an established safety and efficacy record.
2. Abilify Maintena provided the reference product and clinical infrastructure.
3. The development program could rely heavily on pharmacokinetic bridging and established disease indications.
4. Prescribers already familiar with aripiprazole required limited education.

The product does not have the competitive profile of a new chemical entity. Its commercial protection depends primarily on formulation, delivery-system, manufacturing, and method-of-use patents, together with brand adoption and the operational complexity of injectable products.

What is the market opportunity for Abilify Asimtufii?

The addressable market consists of adults with schizophrenia or bipolar I disorder who are appropriate candidates for long-acting injectable therapy. The largest opportunity is conversion from monthly Abilify Maintena rather than direct displacement of oral aripiprazole.

Market drivers

Several factors support adoption:

• Lower injection frequency than monthly aripiprazole.
• Potential improvement in treatment persistence and appointment adherence.
• Reduced clinic administration burden.
• Familiarity with aripiprazole’s efficacy and tolerability profile.
• Growth in use of long-acting injectables for patients with adherence challenges.
• Ability to preserve the aripiprazole brand franchise after generic oral competition.

The commercial opportunity is constrained by the need for clinical stabilization, injection-site administration, prior authorization, and reimbursement differences between pharmacy and medical benefits. The product also competes against longer-interval therapies. Aristada can provide intervals of up to six months, while Invega Hafyera also offers six-month dosing for eligible patients.

Patient and payer economics

For payers, the relevant comparison is not only acquisition cost. A long-acting injectable may reduce relapse-related hospitalization, emergency care, and treatment interruption, but these savings depend on patient selection and adherence. Abilify Asimtufii is likely to command a premium to oral aripiprazole and may carry a premium or comparable price to Abilify Maintena on an annual treatment basis.

For providers, the two-month schedule can reduce injection visits but may require inventory management and administration infrastructure. In the U.S., reimbursement and site-of-care economics can influence whether the product is dispensed through a specialty pharmacy or purchased and administered by a clinic.

How does Abilify Asimtufii compare with Abilify Maintena?

Abilify Asimtufii is best understood as a franchise-extension product.

Commercial factor	Abilify Asimtufii	Abilify Maintena
Injection interval	Every two months	Monthly
Strategic role	Premium or convenience upgrade	Established base product
Primary conversion source	Maintena patients and selected oral patients	Oral aripiprazole and other antipsychotics
Prescriber familiarity	High because of shared active ingredient	High
Administration burden	Lower visit frequency	Higher visit frequency
Cannibalization risk	Material	Asimtufii may replace Maintena volume
Franchise effect	Extends lifecycle and supports pricing	Provides installed base for conversion

Cannibalization is not necessarily negative. If Asimtufii produces higher net sales per patient or improves persistence, the manufacturer can increase franchise economics even as Maintena unit volume declines. The key metric is combined revenue and contribution margin from aripiprazole long-acting injectables, not Maintena volume alone.

What are the financial prospects for Abilify Asimtufii?

Standalone Asimtufii sales are not separately reported in the public financial disclosures of Otsuka or Lundbeck. The most reliable financial assessment therefore uses franchise-level indicators.

Revenue trajectory

The expected trajectory has four stages:

Period	Commercial phase	Financial implication
2023	U.S. launch	Initial revenue contribution; launch and market-access costs
2024-2025	Early conversion	Rising Asimtufii adoption, with some Maintena cannibalization
2026-2028	Franchise optimization	Greater contribution from two-month dosing and international expansion
After major patent or exclusivity loss	Competitive defense	Pricing pressure, conversion management, and manufacturing differentiation

The product should have a favorable gross-margin profile once launch costs normalize. It uses the established aripiprazole active ingredient and builds on existing manufacturing, clinical, and commercial infrastructure. Its economics are less dependent on broad new-patient acquisition than on retaining existing franchise patients and shifting them to a higher-value formulation.

Key financial sensitivities

The principal variables are:

1. Conversion rate from Abilify Maintena.
2. Net price after rebates and payer discounts.
3. Share of eligible patients receiving long-acting injectable treatment.
4. Duration of treatment persistence.
5. International approval and reimbursement.
6. Timing of generic challenges to earlier aripiprazole injectable products.
7. Competitive uptake of longer-interval products, including six-month injectables.

Lundbeck’s financial reporting has historically identified Abilify Maintena as a material growth product, while Otsuka reports pharmaceutical performance through broader corporate and product categories. Investors should not treat total aripiprazole franchise revenue as equivalent to Asimtufii revenue.

What patents protect Abilify Asimtufii?

Protection for Abilify Asimtufii is expected to center on formulation and delivery technology rather than composition of matter for aripiprazole. Aripiprazole itself is an old active ingredient, and its original compound patents expired years ago.

Potential protection categories include:

• Extended-release injectable formulations.
• Particle-size and crystalline-form characteristics.
• Drug-release profiles over approximately two months.
• Stabilization and suspension systems.
• Dosage strengths and injection regimens.
• Methods for switching stabilized patients from monthly to two-month dosing.
• Manufacturing processes and sterile injectable production.

The Orange Book status must be evaluated against the specific approved NDA and listed patents. The existence of a patent does not establish that it will block a generic, and an Orange Book listing does not establish validity or enforceability.

What is the exclusivity position?

Abilify Asimtufii did not receive the standard five-year new chemical entity exclusivity because aripiprazole was previously approved. The product’s practical exclusivity is therefore patent-driven and supported by regulatory complexity, manufacturing requirements, and brand loyalty.

The principal commercial protection is likely to be strongest before generic applicants can obtain approval for an equivalent extended-release injectable formulation. A generic applicant would need to address formulation performance, injectable manufacturing, pharmacokinetics, stability, and device or presentation requirements.

Are there Paragraph IV challenges to Abilify Asimtufii?

No widely reported Paragraph IV litigation involving Abilify Asimtufii had materially affected the product’s market position through the publicly available launch-period disclosures. The absence of reported litigation does not eliminate future challenge risk.

A Paragraph IV filing could target patents covering:

• The two-month dosing regimen.
• Extended-release suspension characteristics.
• Manufacturing methods.
• Pharmacokinetic performance.
• Switching or maintenance treatment methods.

Generic entry is more difficult for a complex injectable than for an oral tablet. Applicants must demonstrate pharmaceutical equivalence and satisfy FDA requirements for injectable quality, sterility, release characteristics, and manufacturing controls. These requirements can delay entry even when patent disputes are resolved.

What is the biosimilar risk for Abilify Asimtufii?

Biosimilar risk is not applicable because Abilify Asimtufii contains a chemically synthesized small-molecule drug, not a biologic. Any follow-on product would proceed through the abbreviated new drug application pathway or another small-molecule pathway, not the Public Health Service Act biosimilar pathway.

The more relevant risks are:

• Generic aripiprazole tablets reducing the cost of oral therapy.
• Generic or follow-on aripiprazole long-acting injectables.
• Competing branded long-acting injectables.
• Formulation-specific patent challenges.
• Payer pressure on branded injectable reimbursement.

What patent litigation and settlement risks affect the product?

The immediate litigation risk is lower than for a mature oral product with numerous generic filers because Asimtufii requires a complex injectable formulation. Risk rises as sales increase and the commercial opportunity becomes large enough to justify formulation development and patent litigation.

Potential settlement structures could include:

• A license with an agreed future generic launch date.
• A royalty-bearing generic supply arrangement.
• Restrictions on launch strength or formulation.
• No-admission settlements resolving patent claims without invalidity findings.

Any future settlement would materially affect valuation because an early authorized or licensed generic could reduce price but preserve some manufacturer economics.

How strong is the patent estate for Abilify Asimtufii?

The estate is commercially useful but structurally narrower than a new molecular-entity estate. Its strength depends on whether the claims cover the specific release profile and formulation used in the approved product, whether alternative formulations can avoid infringement, and whether the patents survive validity challenges.

Patent-estate factor	Assessment
Active ingredient protection	Weak or expired, because aripiprazole is an established compound
Formulation protection	More important and potentially meaningful
Manufacturing protection	Potentially important because sterile injectable processes are difficult to replicate
Method-of-use protection	Useful but vulnerable if claims are narrow or label-based
Regulatory complexity	Moderate to high
Substitution risk	Moderate from other long-acting injectables
Generic development barrier	Higher than for oral aripiprazole

The estate’s practical strength may exceed its nominal patent count because manufacturing scale, sterile fill-finish capacity, clinical experience, and provider contracts create additional barriers. Those barriers are commercial rather than statutory and can erode over time.

What generic launch scenarios exist for Abilify Asimtufii?

Three scenarios are commercially plausible:

Delayed generic entry

The branded product retains strong pricing through the core patent period. Conversion from Maintena continues, and the franchise generates peak revenue before substantial erosion.

At-risk generic launch

A generic applicant launches before final resolution of patent litigation. This can trigger rapid price reductions, payer substitution, and damages exposure if the patents are later upheld.

Authorized or licensed generic entry

The originator controls the timing and economics of follow-on competition. Revenue declines more gradually, but the originator may retain supply, royalty, or distribution economics.

The most likely erosion pattern for a complex injectable is slower than the rapid substitution typically seen after oral tablet exclusivity loss. However, a successful follow-on product with equivalent dosing convenience could produce substantial pricing pressure.

What companies compete with Abilify Asimtufii?

The competitive landscape includes both direct pharmacologic competitors and alternative long-acting treatment strategies.

Competitor	Company	Differentiation
Abilify Maintena	Otsuka/Lundbeck	Same molecule, monthly dosing
Aristada	Alkermes	Aripiprazole lauroxil; intervals up to six months
Invega Sustenna	Johnson & Johnson	Monthly paliperidone
Invega Trinza	Johnson & Johnson	Three-month paliperidone
Invega Hafyera	Johnson & Johnson	Six-month paliperidone
Uzedy	Teva	Monthly or two-month risperidone
Perseris	Teva	Monthly risperidone
Oral generics	Multiple manufacturers	Low-cost daily treatment

Asimtufii’s principal advantage is the combination of established aripiprazole use and reduced dosing frequency. Its principal competitive weakness is that other products can offer longer intervals or different clinical profiles.

What is the geographic coverage and international outlook?

The United States is the most important early market because of its large specialty psychiatry infrastructure, commercial insurance base, and established use of Abilify Maintena. International expansion can increase the product’s duration, but launch timing depends on country-specific regulatory review, reimbursement, injection practices, and patent rights.

European and Asian markets may produce slower uptake where:

• Long-acting injectable use is concentrated in public or hospital systems.
• Price controls limit premium positioning.
• Monthly or oral treatment remains standard.
• Administration reimbursement is less favorable.
• National formularies require comparative cost-effectiveness evidence.

The product’s geographic patent position may differ materially by country. U.S. commercial performance should not be extrapolated directly to global revenue.

Key Takeaways

• Abilify Asimtufii is a two-month aripiprazole long-acting injectable approved by the FDA in February 2023.
• Its main commercial role is to extend the Abilify franchise and convert patients from monthly Abilify Maintena.
• Standalone Asimtufii revenue is not publicly disclosed; financial analysis should use combined aripiprazole injectable sales.
• Revenue growth depends on conversion, persistence, reimbursement, and international expansion.
• Aripiprazole’s active-ingredient patents are not the principal protection. Formulation, delivery, manufacturing, and regimen patents matter more.
• Biosimilar risk does not apply. Generic and follow-on injectable risk does.
• Longer-interval competitors, especially six-month products, represent the clearest branded threat.
• The product’s complex injectable manufacturing requirements should slow, but not eliminate, eventual generic competition.
• The financial outcome is likely to be a franchise extension with potential premium economics, partly offset by Maintena cannibalization.

Frequently Asked Questions

Is Abilify Asimtufii more effective than Abilify Maintena?

The products contain the same active ingredient and treat the same approved conditions. Asimtufii’s primary advantage is dosing convenience, not a demonstrated broad efficacy advantage over Maintena.

Can patients switch directly from oral aripiprazole to Abilify Asimtufii?

Patients generally must be stabilized on oral aripiprazole or an appropriate aripiprazole regimen before receiving the long-acting injectable. The FDA label governs initiation, oral supplementation, and switching procedures.

Does Abilify Asimtufii have orphan-drug exclusivity?

No. The approved indications are common psychiatric disorders and do not represent orphan-drug exclusivity.

Will generic oral aripiprazole reduce Abilify Asimtufii sales?

It can pressure the franchise by lowering the cost of daily therapy. The effect should be moderated by adherence advantages, clinical preference, and the distinct value proposition of long-acting injection.

Is Abilify Asimtufii available in a six-month formulation?

No. Abilify Asimtufii is administered every two months. Six-month alternatives exist in other long-acting injectable franchises, including paliperidone products and certain aripiprazole lauroxil regimens.

References

1. U.S. Food and Drug Administration. (2023). Abilify Asimtufii prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2023). FDA approves new formulation of aripiprazole for schizophrenia and bipolar I disorder maintenance treatment. https://www.fda.gov
3. Otsuka Pharmaceutical Co., Ltd. (2024). Annual report and financial information. https://www.otsuka.com
4. H. Lundbeck A/S. (2024). Annual report 2023. https://www.lundbeck.com
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugsatfda
6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, NDA 217006. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm